t(2;19)(p11;p13)
2007-08-01 Jean-Loup Huret Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
Acute myeloid leukaemia (AML)
Phenotype stem cell origin
One de novo AML (M2 type), and a therapy related AML (t-AML)
Epidemiology
The de novo AML was a 11 year old girl; the t-AML case was a 58 year old female patient who had been treated for ovary carcinoma with melphalan 1.5 yrs before.
Prognosis
No complete remission (CR) in the de novo case; CR was obtained but a relapse occurred and the patient died 3 months after diagnosis in the therapy related case.
Genes Involved and Proteins
Note
Genes involved are unknown.
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 3167210 | 1988 | Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. | Larson RA et al |
Citation
Jean-Loup Huret
t(2;19)(p11;p13)
Atlas Genet Cytogenet Oncol Haematol. 2007-08-01
Online version: http://atlasgeneticsoncology.org/haematological/1288/t(2;19)(p11;p13)
